Izindaba

I-NEW DELHI, Juni 22 (Xinhua) — I-Covaxin yomkhiqizi wemithi yokugoma eNdiya i-Bharat Biotech ikhombise ukusebenza kahle ngamaphesenti angu-77.8 ezivivinyweni zesigaba sesi-3, kusho abezindaba abaningi bendawo ngoLwesibili.

“I-Covaxin kaBharat Biotech isebenza kahle ngamaphesenti angu-77.8 ekuvikeleni i-COVID-19, ngokusho kwedatha evela ezivivinyweni zesigaba III ezenziwe kubahlanganyeli abangu-25,800 kulo lonke elaseNdiya,” kusho umbiko.

Izinga lokusebenza kahle liphume ngoLwesibili ngemuva kokuba ikomidi lochwepheshe bezihloko ze-Drugs Controller General of India (DCGI) lihlangane futhi laxoxa ngemiphumela.

Le nkampani yemithi yayithumele idatha yesilingo sesigaba sesi-3 somuthi wokugoma ku-DCGI ngempelasonto.

Imibiko ithi inkampani kulindeleke ukuthi ibambe umhlangano "wangaphambi kokuthunyelwa" neziphathimandla ze-World Health Organisation ngoLwesithathu, ukuze kuxoxwe ngeziqondiso zokuthunyelwa kokugcina kwedatha nemibhalo edingekayo.

I-India yaqala ukugomela i-COVID-19 ngobuningi ngoJanuwari 16 ngokunikeza imijovo emibili eyenziwe eNdiya, okuyi-Covishield kanye ne-Covaxin.

I-Serum Institute of India (SII) ikhiqiza i-Covishield yase-AstraZeneca-Oxford University, kanti i-Bharat Biotech ibambisene ne-Indian Council of Medical Research (ICMR) ekukhiqizeni i-Covaxin.

Umuthi wokugomela i-Sputnik V owenziwe eRussia nawo usuqalile ukusetshenziswa ezweni.